Contact activation of human plasma prorenin in vitro. 1981

A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan

Acid activation of plasma prorenin occurs during dialysis to pH 3.3. and also during subsequent dialysis to pH 7.4. The latter, alkaline phase, involves Hageman factor-dependent formation of kallikrein, which in turn activates prorenin. The present study evaluates whether prorenin activation always occurs whenever kallikrein is activated in plasma. TAME esterase activity was used as a measure of plasma kallikrein activity an increase was observed during the alkaline phase of acid activation of prorenin. TAME esterase activity was absent when Hageman factor- or prekallikrein-deficient plasmas were similarly assayed and prorenin was not activated. Kaolin treatment of normal plasma rapidly increased TAME esterase activity at both 25 degrees and -4 degrees C, but no prorenin activation occurred. Similar changes in TAME esterase activity were observed in acid-treated plasma, in which setting prorenin was activated. No change in TAME esterase or renin activity occurred after addition of kaolin to acid-treated plasma deficient in Hageman factor; however, both enzymatic activities increased slightly in acidified prekallikrein-deficient plasma. Mixtures of these deficient plasmas exhibited normal kaolin activation of both TAME esterase and prorenin after acidification. Thus both Hageman factor and prekallikrein are needed for optimal contact activation of prorenin. These results demonstrate that prorenin activation does not always occur when active kallikrein is present in plasma. Prior acidification appears to be a prerequisite. Acidified prorenin may be more susceptible to cleavage; alternatively, competing substrates and/or inhibitors of kallikrein may be destroyed at acid pH, thereby permitting kallikrein to activate prorenin. Under normal conditions, activation of the plasma kallikrein-kinin system appears unlikely to result in activation of prorenin in vivo.

UI MeSH Term Description Entries
D007616 Kaolin The most common mineral of a group of hydrated aluminum silicates, approximately H2Al2Si2O8-H2O. It is prepared for pharmaceutical and medicinal purposes by levigating with water to remove sand, etc. (From Merck Index, 11th ed) The name is derived from Kao-ling (Chinese: "high ridge"), the original site. (From Grant & Hackh's Chemical Dictionary, 5th ed) Kaolinite
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D011288 Prekallikrein A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease. Fletcher Factor,Plasma Prokallikrein,Kallikreinogen,Plasma Prokallikrein A,Factor, Fletcher,Prokallikrein A, Plasma,Prokallikrein, Plasma
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D003956 Dialysis A process of selective diffusion through a membrane. It is usually used to separate low-molecular-weight solutes which diffuse through the membrane from the colloidal and high-molecular-weight solutes which do not. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Dialyses
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004792 Enzyme Precursors Physiologically inactive substances that can be converted to active enzymes. Enzyme Precursor,Proenzyme,Proenzymes,Zymogen,Zymogens,Precursor, Enzyme,Precursors, Enzyme
D005175 Factor XII Deficiency An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time. Hageman Trait,Coagulation Factor 12 Deficiency,Deficiency, Factor 12,Deficiency, Factor Twelve,Deficiency, Factor XII,Factor 12 Deficiency,Factor Twelve Deficiency,Hageman Factor Deficiency,Deficiencies, Factor 12,Deficiencies, Factor Twelve,Deficiencies, Factor XII,Deficiency, Hageman Factor,Factor 12 Deficiencies,Factor 12 Deficiency,Factor Deficiency, Hageman,Factor Twelve Deficiencies,Factor XII Deficiencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations

Related Publications

A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
April 1984, The Journal of laboratory and clinical medicine,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
June 1975, Circulation research,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
November 1989, Bollettino della Societa italiana di biologia sperimentale,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
July 1987, Hypertension (Dallas, Tex. : 1979),
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
December 1986, Journal of hypertension,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
September 1991, Canadian journal of physiology and pharmacology,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
January 1983, Advances in experimental medicine and biology,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
January 1985, Nihon Jinzo Gakkai shi,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
January 1989, Canadian journal of physiology and pharmacology,
A L Blumberg, and J E Sealey, and S A Atlas, and J H Laragh, and B Dharmgrongartama, and A P Kaplan
December 1987, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!